September 17, 2025

J&J’s Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials

7 hours ago talkbio0Tagged Dental Plaque, deucravacitinib, IL-23 receptor antagonist, JNJ-2113, Johnson & Johnson, Myers, oral peptide, Phase 3 clinical trial, Psoriasis, skin clearance, Sotyktu

Icotrokinra; JNJ-2113; Johnson & Johnson; IL-23 receptor antagonist; Sotyktu; deucravacitinib; plaque psoriasis; Phase 3 clinical trial; skin clearance; oral peptide; Bristol Myers Squibb

FDA Cracks Down on Misleading Drug Ads in Major Pharmaceutical Companies

7 hours ago talkbio0Tagged Crackdown, Misleading Drug Ads, pharmaceutical companies, United States Food and Drug Administration

FDA; Misleading Drug Ads; Pharmaceutical Companies; Crackdown

Ollin Biosciences Launches with $100M to Challenge Roche in Eye Disease Market

8 hours ago talkbio0Tagged Ang2, Biosciences, Clinical Trials, Disorder of eye, Macular edema due to diabetes mellitus, Ollin, OLN324, Roche (company), Vabysmo, Vascular Endothelial Growth Factor A, Wet AMD

Ollin Biosciences; Roche; eye disease; biotech; VEGF-A; Ang2; wet AMD; diabetic macular edema; clinical trial; OLN324; Vabysmo

Eli Lilly’s Oral GLP-1 Orforglipron Outperforms Semaglutide in Diabetes and Weight Loss Trials

8 hours ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Eli Lilly, Glucagon-Like Peptide 1, Nordisk, Oral cavity, orforglipron, semaglutide, Weight Loss

Lilly; orforglipron; oral GLP-1; semaglutide; type 2 diabetes; weight loss; phase 3 trial; Novo Nordisk

Next-Generation Psoriasis Drugs Aim to Reshape Treatment Landscape

8 hours ago talkbio0Tagged Approved, Clinical Trials, icotrokinra, inhibitors, interleukin-23, next-generation biologics, oral peptides, Piclidenoson, TYK2 gene, United States Food and Drug Administration, Vunakizumab

psoriasis; next-generation biologics; icotrokinra; IL-23 inhibitors; oral peptides; TYK2 inhibitors; vunakizumab; piclidenoson; clinical trials; FDA approval